Molgramostim

DB12525InvestigationalProtein Based Therapies

Molgramostim has been used in trials studying the treatment of Bronchiectasis, Cystic Fibrosis, Pulmonary Alveolar Proteinosis, Acute Respiratory Distress Syndrome, and Autoimmune Pulmonary Alveolar Proteinosis.

Mechanism: Pharmacologically active on Granulocyte-macrophage colony-stimulating factor receptor subunit alpha and Cytokine receptor common subunit beta
Curator reviewed
Code names: SCH-39300

Resolves to

Compound

UNIIB321AL142JCAS99283-10-0

Clinical / RWD

RxNorm70161ATCL03AA03

Targets

P15509CSF2RAP32927CSF2RB

What you can answer from here — as of July 11, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

38Drug interactionsStructured to mechanism, not free text

15Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 15 drug categories

10+ReferencesStructured and connected to the statements they support

Which drugs share a target with Molgramostim, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account